Study details
Enrolling now
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
Vanderbilt University Medical Center
NCT IDNCT07189936ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
50
Study length
about 3.5 years
Ages
18+
Locations
1 site in TN
What this study is about
This trial is testing whether a treatment called 2-HOBA can help with immune markers and orthostatic tachycardia in people with Long COVID and POTS. The trial compares 2-HOBA to a placebo (an inactive substance) over 28 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take To Measure levels of circulating monocyte/ T cell doublets at Baseline
- 2.Take To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment
- 3.Take To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment
- +3 more
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Infectious